1. bookVolumen 64 (2014): Edición 3 (September 2014)
Detalles de la revista
License
Formato
Revista
eISSN
1846-9558
Primera edición
28 Feb 2007
Calendario de la edición
4 veces al año
Idiomas
Inglés
Acceso abierto

Rosuvastatin, Sildenafil and Their Combination in Monocrotaline-Induced Pulmonary Hypertension in Rat

Publicado en línea: 08 Oct 2014
Volumen & Edición: Volumen 64 (2014) - Edición 3 (September 2014)
Páginas: 345 - 353
Aceptado: 15 May 2014
Detalles de la revista
License
Formato
Revista
eISSN
1846-9558
Primera edición
28 Feb 2007
Calendario de la edición
4 veces al año
Idiomas
Inglés

1. J. K. Liao and U. Laufs, Pleiotropic effects of statins, Annu. Rev. Pharmacol. Toxicol. 45 (2005) 89-118; DOI: 10.1146/annurev.pharmtox.45.120403.095748.10.1146/annurev.pharmtox.45.120403.095748269458015822172Search in Google Scholar

2. S. Wolfrum, K. S. Jensen and J. K. Liao, Endothelium-dependent effects of statins, Arterioscler. Thromb. Vasc. Biol. 23 (2003) 729-736; DOI: 10.1161/01.ATV.0000063385.12476.A7.10.1161/01.ATV.0000063385.12476.A712615672Search in Google Scholar

3. L. Taraseviciene-Stewart, R. Scerbavicius, K. H. Choe, C. Cool, K. Wood, R. M. Tuder, N. Burns, M. Kasper and N. F. Voelkel, Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension, Am. J. Physiol. Lung Cell Mol. Physiol. 291 (2006) L668-L676; DOI: 10.1152/ ajplung.00491.2005.Search in Google Scholar

4. R. E. Girgis, D. Li, X. Zhan, J. G. Garcia, R. M. Tuder, P. M. Hassoun and R. A. Johns, Attenuation of chronic hypoxic pulmonary hypertension by simvastatin, Am. J. Physiol. Heart Circ. Physiol. 285 (2003) H938-945; DOI: 10.1152/ajpheart.01097.2002.10.1152/ajpheart.01097.200212750068Search in Google Scholar

5. F. Simko, Statins: a perspective for left ventricular hypertrophy treatment, Eur. J. Clin. Invest. 37 (2007) 681-691; DOI: 10.1111/j.1365-2362.2007.01837.x.10.1111/j.1365-2362.2007.01837.x17696957Search in Google Scholar

6. P. J. Delahoy, D. J. Magliano, K. Webb, M. Grobler and D. Liew, The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis, Clin. Ther. 31 (2009) 236-244; DOI: 10.1016/j.clinthera.2009.02.017.10.1016/j.clinthera.2009.02.01719302897Search in Google Scholar

7. M. Satoh and A. Satoh, 3-Hydroxy-3-methylglutaryl (HMG)-COA reductase inhibitors and phosphodiesterase type V inhibitors attenuate right ventricular pressure and remodeling in a rat model of pulmonary hypertension, J. Pharm. Pharm. Sci. 11 (2009) 118s-130s.Search in Google Scholar

8. X. Sun and D. D. Ku, Rosuvastatin provides pleiotropic protection against pulmonary hypertension, right ventricular hypertrophy, and coronary endothelial dysfunction in rats, Am. J. Physiol. Heart Circ. Physiol. 294 (2008) H801-H809; DOI: 10.1152/ajpheart.01112.2007.10.1152/ajpheart.01112.200718055512Search in Google Scholar

9. Y. Pei, P. Ma, X. Wang, W. Zhang, X. Zhang, P. Zheng, L. Yan, Q. Xu and G. Dai, Rosuvastatin attenuates monocrotaline-induced pulmonary hypertension via regulation of Akt/eNOS signaling and asymmetric dimethylarginine metabolism, Eur. J. Pharmacol. 666 (2011) 165-172; DOI: 10.1016/j. ejphar.2011.05.035.Search in Google Scholar

10. V. G. DeMarco, J. Habibi, A. T. Whaley-Connell, R. I. Schneider, J. R. Sowers, B. T. Andresen, A. A. Gutweiler, L. Ma, M. S. Johnson, C. M. Ferrario and K. C. Dellsperger, Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat, Am. J. Physiol. Heart Circ. Physiol. 297 (2009) H1128-1139; DOI: 10.1152/ajpheart.00048.2009.10.1152/ajpheart.00048.2009275597619633211Search in Google Scholar

11. T. Kuang, J. Wang, B. Pang, X. Huang, E. D. Burg, J. X. Yuan and C. Wang, Combination of sildenafil and simvastatin ameliorates monocrotaline-induced pulmonary hypertension in rats, Pulm. Pharmacol. Ther. 23 (2010) 456-464; DOI: 10.1016/j.pupt.2010.02.003.10.1016/j.pupt.2010.02.003310805920188205Search in Google Scholar

12. L. Zhao, A. Sebkhi, O. Ali, B. Wojciak-Stothard, L. Mamanova, Q. Yang, J. Wharton and M. R. Wilkins, Simvastatin and sildenafil combine to attenuate pulmonary hypertension, Eur. Respir. J. 34 (2009) 948-957; DOI: 10.1183/09031936.00143508.10.1183/09031936.0014350819797670Search in Google Scholar

13. D. S. Lee, Y. K. Kim and Y. W. Jung, Simvastatin, sildenafil and their combination in monocrotaline induced pulmonary arterial hypertension, Korean Circ. J. 40 (2010) 659-664; DOI: 10.4070/ kcj.2010.40.12.659.10.4070/kcj.2010.40.12.659302534021267389Search in Google Scholar

14. X. L. Li, R. J. Guan, Q. H. Xu and Z. Y. Wu, [Effects of rosuvastatin on monocrotaline-induced pulmonary artery hypertension in rats], Zhonghua Xin Xue Guan Bing Za Zhi. 39 (2011) 247-253.Search in Google Scholar

15. R. T. Schermuly, K. P. Kreisselmeier, H. A. Ghofrani, A. Samidurai, S. Pullamsetti, N. Weissmann, C. Schudt, L. Ermert, W. Seeger and F. Grimminger, Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension, Circ. Res. 94 (2004) 1101-1108; DOI: 10.1161/01.RES.0000126050.41296.8E.10.1161/01.RES.0000126050.41296.8E15031263Search in Google Scholar

16. M. Jasińska-Stroschein, J. Owczarek, A. Łuczak, and D. Orszulak-Michalak, The beneficial impact of fasudil and sildenafil on monocrotaline-induced pulmonary hypertension in rats: A hemodynamic and biochemical study, Pharmacology 91 (2013) 178-184; DOI: 10.1159/000346921.10.1159/00034692123428587Search in Google Scholar

17. N. Galiè, M. M. Hoeper, M. Humbert, A. Torbicki, J. L. Vachiery, J. A. Barbera, M. Beghetti, P. Corris, S. Gaine, J. S. Gibbs, M. A. Gomez-Sanchez, G. Jondeau, W. Klepetko, C. Opitz, A. Peacock, L. Rubin, M. Zellweger and G. Simonneau, ESC Committee for Practice Guidelines (CPG): Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT), Eur. Heart. J. 30 (2009) 2493-2537; DOI: 10.1093/eurheartj/ehp297. 10.1093/eurheartj/ehp29719713419Search in Google Scholar

18. M. R. Wilkins, O. Ali, W. Bradlow, J. Wharton, A. Taegtmeyer, C. J. Rhodes, H. A. Ghofrani, L. Howard, P. Nihoyannopoulos, R. H. Mohiaddin and J. S. Gibbs, Simvastatin Pulmonary Hypertension Trial (SiPHT) Study Group, Simvastatin as a treatment for pulmonary hypertension trial, Am. J. Respir. Crit. Care Med. 181 (2010) 1106-1113; DOI: 10.1164/rccm.2009111-699OC.10.1164/rccm.2009111-699OCSearch in Google Scholar

19. C. Transon, T. Leemann and P. Dayer, In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors, Eur. J. Clin Pharmacol. 50 (1996) 209-215.10.1007/s0022800500948737761Search in Google Scholar

20. W. J. Zeng, C. M. Xiong, L. Zhao, G. L. Shan, Z. H. Liu, F. Xue Q. Gu, X. H. Ni, Z. H. Zhao, X. S. Cheng, M. R. Wilkins and J. G. He, Atorvastatin in pulmonary arterial hypertension (APATH) study, Eur. Respir. J. 40 (2012) 67-74; DOI: 10.1183/09031936.00149011.10.1183/09031936.0014901122362846Search in Google Scholar

21. E. Abulhul, K. McDonald, R. Martos, D. Phelan, J. P. Spiers, M. Hennessy, J. Baugh, C. Watson, C. O’Loughlin and M. Ledwidge, Long-term statin therapy in patients with systolic heart failure and normal cholesterol: effects on elevated serum markers of collagen turnover, inflammation, and B-type natriuretic peptide, Clin. Ther. 34 (2012) 91-100; DOI: 10.1016/j.clinthera.2011.11.002.10.1016/j.clinthera.2011.11.00222154198Search in Google Scholar

22. Y. Teshima, K. Yufu, H. Akioka, T. Iwao, F. Anan, M. Nakagawa, H. Yonemochi, N. Takahashi, M. Hara and T. Saikawa, Early atorvastatin therapy improves cardiac function in patients with acute myocardial infarction, J. Cardiol. 53 (2009) 58-64; DOI: 10.1016/j.jjcc.2008.08.008.10.1016/j.jjcc.2008.08.00819167639Search in Google Scholar

23. D. Chen, D. Zhou, J. Qian, F. Chen, L. Guan, L. Dong and J. Ge, Atorvastatin prevents dehydromonocrotaline- induced pulmonary hypertension in beagles, Exp Lung Res. 38 (2012) 333-343; DOI: 10.3109/01902148.2012.702852.10.3109/01902148.2012.70285222888849Search in Google Scholar

24. S. Yigitaslan and B. Sirmagul, Relation of bosentan, iloprost, and sildenafil with growth factor levels in monocrotaline-induced pulmonary hypertension, Clin. Exp. Hypertens. 34 (2012) 222-229; DOI: 10.3109/10641963.2011.631652.10.3109/10641963.2011.63165222468718Search in Google Scholar

25. K. T. Mouchaers, I. Schalij, M. A. de Boer, P. E. Postmus, V. W. van Hinsbergh, G. P. van Nieuw Amerongen, A. Vonk Noordegraaf and W. J. van der Laarse, Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil, Eur. Respir. J. 36 (2010) 800-807; DOI: 10.1183/09031936.00130209. 10.1183/09031936.0013020920351034Search in Google Scholar

Artículos recomendados de Trend MD

Planifique su conferencia remota con Sciendo